788 Results
Sort By:
Published on October 24, 2019
The blood-based cell-free DNA (cfDNA) HELIXAFE test can detect solid tumors even before they develop, according to a study published in the journal Cell Death & Disease by an international group of experts coordinated by Bioscience Genomics, a research entity formed by the collaboration between the University of Rome Tor Vergata and Bioscience…
Published on August 23, 2019
Researchers at Moffitt Cancer Center have partnered with investigators at the Dana-Farber Cancer Institute and Foundation Medicine to develop what Moffitt said was the largest descriptive genomic analysis to date of patients with Merkel cell carcinoma (MCC). MCC is a rare aggressive skin tumor that is diagnosed in approximately 2,000…
Published on July 9, 2019
Biodesix said it will partner with Thermo Fisher Scientific to develop a next-generation sequencing (NGS) assay for use as a blood-based diagnostic solution for advanced non-small cell lung cancer (NSCLC). Biodesix plans to obtain FDA premarket approval for the diagnostic by using Thermo Fisher’s Ion Torrent Oncomine Pan-Cancer Cell-Free Assay…
Published on June 26, 2019
Researchers have uncovered three ways FOXA1 (Forkhead box A1) gene mutations override normal biology to drive an estimated one-third of prostate cancers. Dubbed FAST, FURIOUS and LOUD, the three mechanisms are described in a paper by researchers at the University of Michigan Rogel Cancer Center. Their findings were published in Nature,…
Published on June 6, 2019
A new compound has been discovered that disables a key DNA repair pathway involved In cancer drug resistance. The potential drug, found by researchers at MIT and Duke University, enhances the effects of cisplatin, a popular cancer chemotherapy. The paper appears in the June 6 issue of Cell. Cisplatin is a…
Published on March 27, 2019
Multidimensional, computationally rich approaches represent the next wave of innovation, taking personalized medicine to the next level, while demanding more of practitioners, who in turn demand convenient, informative updates on the ever-changing state of clinical omics,” Clinical OMICs noted in introducing itself to readers with its first issue, dated April…
Published on March 21, 2019
Scientists at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, report the development of LumosVar, a computer program that can help identify cancer-causing mutations from patient tumor samples. The study (“Leveraging Spatial Variation in Tumor Purity for Improved Somatic Variant Calling of Archival Tumor Only Samples”) appears in Frontiers in Oncology.…
Published on February 27, 2019
Biocept said today it will partner with Providence St. Joseph Health, Southern California and its wholly-owned affiliates—Providence Saint John’s Health Center and the John Wayne Cancer Institute—on a study designed to validate the use of cerebrospinal fluid (CSF) as a specimen type with Biocept's Target Selector liquid biopsy platform in…
Published on February 1, 2019
More than 60 healthcare stakeholders have signed a letter urging the Centers for Medicare and Medicaid Services (CMS) to revise its interpretation of the National Coverage Determination (NCD) for Next Generation Sequencing (NGS). The 63 stakeholders—which include patients, providers, academic medical centers, laboratories, and diagnostic manufacturers—have sent a letter to…
Published on January 28, 2019
Molecular diagnostics company Biocept has launched the first in what will be a series of liquid biopsy test kits for cancer with the intention of increasing the use of its Target Selector ctDNA testing platform. The first kit, available for research-use-only (RUO), is for the detection of the EGFR oncogene…
Published on December 19, 2018
Biocept will apply Prognos’ artificial intelligence (AI) platform toward the use of its clinical laboratory diagnostics for precision oncology, through a collaboration whose value was not disclosed. The companies have signed a software license and laboratory data supply agreement, through which Biocept agreed to supply de-identified data from its liquid…
Published on December 7, 2018
Illumina said it will provide a new high-density genotyping array at no charge to the NIH’s All of Us Research Program. The sequencing giant’s Infinium Global Diversity Array will enable the processing of up to 1 million samples by the three genome centers that were awarded a total $28.6 million…
Published on November 7, 2018
Researchers at Georgia Institute of Technology (Georgia Tech) have developed a new open-source decision support tool designed to help clinicians chose the chemotherapy drug best suited for individual patients. The open-source support vector machine (SVM)-based algorithm predicted the chemotherapy drug that provided the best outcome with greater than 80% accuracy,…
Published on November 1, 2018
Widespread study of circulating tumor cells (CTCs) began in the early 2000s. Since then, the goal has been to replace expensive and invasive surgical biopsies with relatively simple and inexpensive CTC-based liquid biopsies. However, the translation of CTC-based liquid biopsy technology from research labs to the clinic has been moving…
Published on September 14, 2018
Bristol-Myers Squibb (BMS) plans to use Natera's Signatera custom circulating tumor DNA (ctDNA) assay in a Phase II study designed to assess the pharma giant’s cancer immunotherapy Opdivo (nivolumab) as an adjuvant treatment for non-small cell lung cancer (NSCLC). Under the collaboration, whose value was not disclosed, BMS will use…